SEC Tracker
Get the app

ARCA biopharma ORKA

ARCA biopharma Q3 FY23: revenue $0; diluted EPS −$0.10

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers ARCA biopharma reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$0No year-earlier figure tagged10-Q income statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
  2. Net income−$1.4MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.10No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$38.5MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations−$1.7MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when ARCA biopharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. CytomX Therapeutics CTMX public float $372M, Jun 30, 2025
  2. Cronos Group CRON public float $380M, Jun 30, 2025
  3. REGENXBIO RGNX public float $385M, Jun 30, 2025
  4. Capricor Therapeutics CAPR public float $399M, Jun 30, 2025
  5. Cryoport CYRX public float $400M, Jun 30, 2025